The present disclosure provides a system for the expression of target protein in conjunction with enhancer protein. The enhancer protein may be a viral protein that blocks nucleocytoplasmic transport. Also provided are polynucleotides, vectors, and cells comprising target protein and enhancer protein nucleic acid sequences.

Disclosed herein are recombinant polypeptides derived from FBP1 and FBP2. Also disclosed herein are recombinant expression vectors and recombinant host cells for producing the aforesaid recombinant polypeptides. The recombinant polypeptides are proven to be useful and effective in producing a picornavirus with a type I internal ribosome entry site (IRES), so as to facilitate the preparation of a viral vaccine.

Severe Acute Respiratory Syndrome Coronavirus 2 antigen virus-like particles (VLPs) and recombinant immune complexes (RICs) are described, along with methods of making said VLPs and RICs in plants and using said VLPs and RICs to induce an immune response in a subject.

The present invention relates to killed/inactivated and/or recombinant Senecavirus A immunogenic compositions and vaccines, and methods of preventing or treating animals in need of with such an immunogenic compositions and vaccines.

A method of treating cancer in a subject that includes administering in situ to the cancer a therapeutically effective amount of a plant virus or virus-like particle to the subject.

Provided are a series of polypeptides with antiviral activity. The present invention provides a new strategy for preventing and controlling Enterovirus such as EV71, CVA16, CVA6, CVB3, and CVB5 viruses and provides a new theoretical basis for accelerating the research and development of a polypeptide small molecule drug against Enterovirus such as EV71, CVA16, CVA6, CVB3, and CVB5 viruses.

A method of treating cancer in a subject in need thereof includes administering in situ to the cancer a therapeutically effective amount of a virus or virus-like particle.

The present disclosure provides a system for the expression of target protein in conjunction with enhancer protein. The enhancer protein may be a viral protein that blocks nucleocytoplasmic transport. Also provided are polynucleotides, vectors, and cells comprising target protein and enhancer protein nucleic acid sequences.

The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.

Provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing a chimeric antigen receptor (CAR) and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing.